Immune modulating therapy for IgA nephropathy: rationale and evidence.
1Division of Nephrology and Immunology, University of Aachen, RWTH Aachen, Germany. juergen.floege@rwth-aachen.de
Seminars in Nephrology
|January 29, 2008
Summary
Immunosuppressive therapy for IgA nephropathy (IgAN) shows mixed results, with supportive care often being the first-line treatment. Optimize supportive care before considering immunosuppression for patients at risk of kidney failure.
Area of Science:
- Nephrology
- Immunology
- Clinical Trials
Background:
- The initial pathogenesis of IgA nephropathy (IgAN) offers limited justification for immunosuppressive therapy.
- Immunosuppression may target secondary inflammation or proteinuria in IgAN.
- Current evidence for immunosuppressive therapy in IgAN is inconsistent.
Purpose of the Study:
- To evaluate the efficacy of immunosuppressive therapy versus supportive care in IgA nephropathy.
- To address the limitations of existing clinical trials in IgAN treatment strategies.
- To provide guidance on the optimal sequencing of supportive and immunosuppressive therapies for IgAN patients.
Main Methods:
- Review of randomized clinical trials on corticosteroid monotherapy, mycophenolate mofetil monotherapy, and combination immunosuppressive therapy in IgAN.
- Analysis of studies evaluating supportive therapy for IgAN.
- Comparison of outcomes, including proteinuria and renal failure, in IgAN patients.
Main Results:
- Some trials suggest benefits of immunosuppression for proteinuria or renal failure in IgAN, but results are not universal.
- Many IgAN studies were designed with outdated supportive care recommendations.
- Recent studies show benefits of supportive therapy, but head-to-head comparisons with immunosuppression are lacking.
Conclusions:
- Optimize supportive therapy for IgA nephropathy patients first.
- Reserve immunosuppressive medication for IgAN patients who do not respond to supportive care and remain at risk for kidney function decline.
- Ongoing clinical trials are needed to resolve the therapeutic dilemma in IgAN management.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:24Nephrotic Syndrome III : Nursing Management
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...